Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper savings to outdo his predecessor.
Related Posts
Trump and Fed Chair Powell could be set on a collision course over interest rates
Though Powell became Fed chair in 2018, after Trump nominated him for the position, the two clashed often about the direction of interest rates.
Lucid CEO says Wall Street misinterpreted $1.75 billion capital raise
Peter Rawlinson said the raise was a timely, strategic business decision to ensure the EV maker has enough capital for its ongoing operations and growth […]
American Eagle says consumer is slowing down, issues weak guidance
American Eagle warned that consumers are slowing down as recession fears swirl.